MYNZ — Mainz Biomed NV Cashflow Statement
0.000.00%
Last trade - 00:00- $10.04m
- $10.09m
- $0.89m
Annual cashflow statement for Mainz Biomed NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.587 | -11.7 | -26.4 | -26.3 | -21.7 |
| Depreciation | |||||
| Non-Cash Items | 0 | 8.54 | 9.85 | 3.56 | 3.49 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.058 | -0.139 | 1.39 | -0.065 | 0.052 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.469 | -3.22 | -14.8 | -21.9 | -17.1 |
| Capital Expenditures | -0.01 | -0.017 | -0.658 | -1.9 | -0.255 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 1.22 | — | — | 0.056 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.01 | 1.2 | -0.658 | -1.9 | -0.199 |
| Financing Cash Flow Items | 0.399 | 0.244 | 0 | -0.934 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.397 | 10.6 | 23.9 | 14.2 | 16.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.081 | 8.6 | 8.41 | -10.1 | -0.835 |